Pancreatic cancer and liver metastases
Standard
Pancreatic cancer and liver metastases : state of the art. / Bellon, Eugen; Gebauer, Florian; Tachezy, Michael; Izbicki, Jakob R; Bockhorn, Maximilian.
in: UPDATES SURG, Jahrgang 68, Nr. 3, 09.2016, S. 247-251.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Pancreatic cancer and liver metastases
T2 - state of the art
AU - Bellon, Eugen
AU - Gebauer, Florian
AU - Tachezy, Michael
AU - Izbicki, Jakob R
AU - Bockhorn, Maximilian
PY - 2016/9
Y1 - 2016/9
N2 - Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome.
AB - Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome.
KW - Antineoplastic Agents/therapeutic use
KW - Global Health
KW - Hepatectomy
KW - Humans
KW - Liver Neoplasms/epidemiology
KW - Morbidity/trends
KW - Palliative Care/methods
KW - Pancreatectomy
KW - Pancreatic Neoplasms/pathology
KW - Survival Rate/trends
U2 - 10.1007/s13304-016-0407-7
DO - 10.1007/s13304-016-0407-7
M3 - SCORING: Review article
C2 - 27832445
VL - 68
SP - 247
EP - 251
JO - UPDATES SURG
JF - UPDATES SURG
SN - 2038-131X
IS - 3
ER -